Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan-Mar;32(1):29-32.
doi: 10.4103/0970-9185.173382.

Comparative study evaluating efficacy of sufentanil versus midazolam in preventing myoclonic movements following etomidate

Mohammad Alipour  1 , Masoumeh Tabari  1 , Azadeh Mokhtari Azad  1
Affiliations

Comparative study evaluating efficacy of sufentanil versus midazolam in preventing myoclonic movements following etomidate

Mohammad Alipour et al. J Anaesthesiol Clin Pharmacol. 2016 Jan-Mar.

Abstract

Background and aims: Myoclonus is a major side-effect following etomidate injection requiring use of medical intervention.

Material and methods: In this double-blinded clinical trial, 50 consecutive patients, randomly received sufentanil 0.2 μg/kg or midazolam 0.015 mg/kg, 90 s before induction of anesthesia with etomidate (0.3 mg/kg). Then, the patients were monitored for any myoclonic movements during anesthesia.

Results: The incidence of myoclonus was 28% in the sufentanil group and 84% in the midazolam group. The frequency and intensity of myoclonus were significantly higher in the midazolam group, compared to the sufentanil group (P < 0.001). Myoclonus duration in the sufentanil and midazolam groups were 5.8 ± 13.2 and 69 ± 47.8 s, respectively (P < 0.0010).

Conclusion: The frequency, intensity and duration of myoclonus in the midazolam group, were significantly more prevalent than the sufentanil group.

Keywords: Etomidate; midazolam; myoclonus; sufentanil.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Bennett JM, Ehrenfeld JM, Markham L, Eagle SS. Anesthetic management and outcomes for patients with pulmonary hypertension and intracardiac shunts and Eisenmenger syndrome: A review of institutional experience. J Clin Anesth. 2014;26:286–93. - PubMed
    1. Li YW, Ma L, Sui B, Cao CH, Liu XD. Etomidate with or without flumazenil anesthesia for stem cell transplantation in autistic children. Drug Metabol Drug Interact. 2014;29:47–51. - PubMed
    1. Liberman MY, Ching S, Chemali J, Brown EN. A closed-loop anesthetic delivery system for real-time control of burst suppression. J Neural Eng. 2013;10:046004. - PMC - PubMed
    1. Kim TK, Park IS. Comparative Study of Brain Protection Effect between Thiopental and Etomidate Using Bispectral Index during Temporary Arterial Occlusion. J Korean Neurosurg Soc. 2011;50:497–502. - PMC - PubMed
    1. Dela Cruz JE, Sullivan DN, Varboncouer E, Milbrandt JC, Duong M, Burdette S, et al. Comparison of procedural sedation for the reduction of dislocated total hip arthroplasty. West J Emerg Med. 2014;15:76–80. - PMC - PubMed